Scientists are anxiously searching for an effective antiviral to combat severe or critical COVID-19, which has already caused over a million deaths worldwide. A new study published on the preprint ...

Response of Circulating Tumor Cells to Systemic Therapy in Patients With Metastatic Breast Cancer: Comparison of Quantitative Polymerase Chain Reaction and Immunocytochemical Techniques PURPOSE: ...

The CDC estimates that one in 68 children in the U.S. are on the autism spectrum. Right now, there are no FDA approved treatments for the disorder or its symptoms, which can include difficulty with ...

Review the side-effects of Suramin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. This phase I study was designed with ...

A CENTURY-old drug has produced “dramatic” results in young children with autism — after just one dose. Suramin is a medication developed in 1916 to treat African sleeping sickness and river blindness ...

Learn everything you need to know about Suramin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

SAN DIEGO (KFSN) -- The CDC estimates that one in 68 children in the U.S. is on the autism spectrum. Right now, there are no FDA approved treatments for the disorder or its symptoms, which can include ...

TARRYTOWN, NY, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire-- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug ...

Administering a single dose of 100-year-old drug suramin -- originally developed to treat African sleeping sickness -- can improve symptoms of autism spectrum disorder (ASD) in children, a study said.

Bladder cancer has an incidence of 30/100 000 per year and three-quarters of patients present with superficial disease. In all, 30% of intermediate-risk superficial bladder tumours will recur within 2 ...